MedTrace Logo

A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis

NCT07326813 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 477

Last updated 2026-04-29

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.

Safety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period.

During the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.

Conditions

Interventions

DRUG

D-2570 Tablet

D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain

DRUG

BMS-986165 Tablet

BMS-986165 is a novel inhibitor targeting TYK2

DRUG

Placebo

A placebo refers to a tablet that has no therapeutic effect on medication

Sponsors & Collaborators

  • InventisBio Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-12
Primary Completion
2027-07-12
Completion
2027-12-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07326813 on ClinicalTrials.gov